PRESS RELEASES More events are coming soon. Keyword Search Year: 20232022202120202019201820172016201520142013 09/06/22 Summary Toggle TRACON Pharmaceuticals Announces $35 Million Non-Dilutive Debt Financing with Runway Growth Capital Printer Friendly PDF Version 08/29/22 Summary Toggle TRACON Pharmaceuticals Announces Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab Printer Friendly PDF Version 08/10/22 Summary Toggle TRACON Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Printer Friendly PDF Version 08/10/22 Summary Toggle TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial Printer Friendly PDF Version 08/08/22 Summary Toggle TRACON Pharmaceuticals Announces Submission of IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab Printer Friendly PDF Version 07/27/22 Summary Toggle TRACON to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 10, 2022 Printer Friendly PDF Version 07/26/22 Summary Toggle TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter Printer Friendly PDF Version 06/02/22 Summary Toggle TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference Printer Friendly PDF Version 05/16/22 Summary Toggle TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference Printer Friendly PDF Version 05/11/22 Summary Toggle TRACON Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update Printer Friendly PDF Version Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
